» Authors » Andres F Cardona

Andres F Cardona

Explore the profile of Andres F Cardona including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 138
Citations 1785
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Saldanha E, Cordeiro de Lima V, Fares A, Corassa M, Gil-Santana L, Arrieta O, et al.
Oncologist . 2025 Mar; 30(2). PMID: 40036771
Introduction: ERBB2-mutant non-small cell lung cancer (NSCLC) represents approximately 1%-4% of all lung adenocarcinomas (LUADs) and has emerged as a distinct molecular subtype. Little is known about NSCLC harboring ERBB2...
2.
Arrieta O, Lozano-Ruiz F, Guijosa A, Soberanis-Pina P, Blake-Cerda M, Gomez-Garcia A, et al.
Front Oncol . 2025 Feb; 15:1438120. PMID: 39963102
Background: As survival rates for lung cancer (LC) patients continue to rise, the adverse impacts of therapies become more relevant. Radiotherapy is known to negatively affect bone health. However, radiotherapy-induced...
3.
Rios-Garcia E, Guijosa A, Caballe-Perez E, Davila-Dupont D, Izquierdo C, Regino A, et al.
Clin Lung Cancer . 2025 Feb; PMID: 39904674
Introduction: Brain metastases (BM) are a prevalent and severe complication of non-small cell lung cancer (NSCLC) that significantly affects quality of life. Although several predictive factors for BM have been...
4.
Parra M, Prada A, Casallas A, Gutierrez-Babativa L, Jaramillo A, Bernal L, et al.
JCO Glob Oncol . 2025 Jan; 11():e2400183. PMID: 39819123
Purpose: Cancer constitutes a significant global health challenge, with projections indicating a continued increase in its prevalence in the foreseeable future. This trend is particularly pronounced in Latin America (LATAM),...
5.
Hernandez-Martinez J, Guijosa A, Flores-Estrada D, Cruz-Rico G, Turcott J, Hernandez-Pedro N, et al.
JCO Glob Oncol . 2024 Dec; 10:e2400338. PMID: 39637345
Purpose: Targeted therapies are indicated for patients with non-small cell lung cancer (NSCLC) and driver tumor mutations. However, real-world studies on the survival benefits of these agents are limited. This...
6.
de Miguel-Perez D, Arroyo-Hernandez M, La Salvia S, Gunasekaran M, Pickering E, Avila S, et al.
J Extracell Vesicles . 2024 Nov; 13(11):e70001. PMID: 39558820
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and has been related to more than 7 million deaths globally since 2019. The association of high...
7.
Arrieta O, Ramos-Ramirez M, Garces-Flores H, Cabrera-Miranda L, Gomez-Garcia A, Soto-Molina H, et al.
Oncologist . 2024 Oct; PMID: 39427228
Background: Using immune checkpoint inhibitors (IO) is a promising approach to maximize clinical benefits for patients with non-small cell lung cancer (NSCLC). PD-L1 expression serves as a predictive factor for...
8.
Turcott J, Miyagui S, Gutierrez Torres S, Cardenas-Fernandez D, Caballe-Perez E, Rios-Garcia E, et al.
Nutr Cancer . 2024 Jul; 76(10):985-993. PMID: 39066469
Sarcopenia in cancer patients often negatively impacts various outcomes. Carboplatin, a first-line chemotherapy for non-small cell lung cancer (NSCLC), is dosed based on body weight, which doesn't account for sarcopenia....
9.
Arrieta O, Arroyo-Hernandez M, Soberanis-Pina P, Viola L, Del Re M, Russo A, et al.
Crit Rev Oncol Hematol . 2024 Jul; 202:104436. PMID: 38977146
Lung cancer (LC) is the leading cause of cancer-related deaths worldwide and the second most common cancer in both men and women. In addition to smoking, other risk factors, such...
10.
Arrieta O, Caballe-Perez E, Hernandez-Pedro N, Romero-Nunez E, Lucio-Lozada J, Castillo-Ruiz C, et al.
Lung Cancer . 2024 Jun; 194:107864. PMID: 38945003
Introduction: Pathogenic or likely pathogenic germline variants (PGVs) in cancer predisposition genes may play a role in lung cancer (LC) susceptibility. However, determining an eligible population for genetic testing remains...